The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern’s Inselspital, Bern University Hospital. Antibodies discovered in the laboratory should inhibit the growth of tumour cells.
Leukaemia stem cells: they have the ability to renew themselves and are resistant to most current, existing cancer therapies (chemotherapy, radiation, targeted medications). Because the cells are responsible for the development of blood cancer, they also regulate the course of disease. The faster they multiply, the faster the illness progresses.